CoChat
Sign Up
Cited by 444

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

COX-2: A Molecular Target for Colorectal Cancer Prevention

Brown, Joanne R., DuBois, Raymond N.·2005·Journal of Clinical Oncology
DOI 10.1200/jco.2005.09.051
Open this paper in CoChat — free account

Abstract

Cyclooxygenase (COX), a key enzyme in the prostanoid biosynthetic pathway, has received considerable attention due to its role in human cancers. Observational and randomized controlled studies in many different population cohorts and settings have demonstrated protective effects of nonsteroidal anti-inflammatory drugs (NSAIDs; the inhibitors of COX activity) for colorectal cancers (CRCs). COX-2, the inducible isoform of cyclooxygenase, is overexpressed in early and advanced CRC tissues, which portends a poor prognosis. Experimental studies have thus identified important mechanisms and pathways by which COX-2 plays an important role in carcinogenesis. Selective COX-2 inhibitors have been approved for use as adjunctive therapy for patients with familial polyposis. The role of COX-2 inhibitors is currently being evaluated for use in wider populations.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.2005.09.051

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 159

  1. 10.1016/S1470-2045(01)00486-7 · DOI
  2. 10.1001/jama.289.10.1288 · DOI
  3. 10.3322/canjclin.54.1.41 · DOI
  4. 10.1093/ageing/26.6.417 · DOI
  5. 10.1016/S1470-2045(02)00680-0 · DOI
  6. 10.1007/BF02358623 · DOI
  7. 10.1007/BF00666099 · DOI
  8. 10.1136/gut.43.4.578 · DOI
  9. 10.1016/0016-5085(95)90235-X · DOI
  10. 10.1016/S0006-2952(00)00576-1 · DOI
  11. Williams CS, Dubois RN: Prostaglandin endoperoxide synthase: Why two isoforms? Am J Physiol 270:G393,1996-G400, · DOI
  12. 10.1016/0163-7258(91)90054-P · DOI
  13. 10.1073/pnas.70.3.899 · DOI
  14. 10.1007/BF00666095 · DOI
  15. 10.1038/nsb1196-927 · DOI
  16. 10.1038/384644a0 · DOI
  17. 10.1038/367243a0 · DOI
  18. 10.1074/jbc.272.14.9280 · DOI
  19. 10.1038/bjc.1977.132 · DOI
  20. 10.1002/jso.2930240119 · DOI
  21. 10.1016/0002-9610(89)90442-X · DOI
  22. 10.1016/S1054-3589(08)60067-8 · DOI
  23. 10.1056/NEJM199112053252301 · DOI
  24. 10.1056/NEJMoa021633 · DOI
  25. 10.1056/NEJMoa021735 · DOI
  26. 10.1056/NEJM200006293422603 · DOI
  27. 10.1136/gut.50.6.857 · DOI
  28. 10.1001/jama.286.8.954 · DOI · Paper page
  29. 10.1056/NEJM200011233432103 · DOI
  30. 10.1001/jama.284.10.1247 · DOI
  31. Mukherjee D, Topol EJ: Cox-2: Where are we in 2003? Cardiovascular risk and Cox-2 inhibitors. Arthritis Res Ther 5:8,2003-11, · DOI
  32. 10.1161/01.CIR.0000127578.21885.3E · DOI
  33. 10.1016/S0140-6736(04)16299-5 · DOI
  34. 10.1093/jnci/85.4.307 · DOI
  35. 10.1016/0002-9343(86)90084-7 · DOI
  36. 10.1007/BF02090382 · DOI
  37. 10.1016/S0092-8674(00)81988-1 · DOI
  38. 10.1111/j.1349-7006.1997.tb00337.x · DOI
  39. 10.1172/JCI119400 · DOI
  40. 10.1093/carcin/19.11.1939 · DOI
  41. 10.1096/fj.01-0390rev · DOI
  42. 10.1016/S0006-2952(01)00857-7 · DOI
  43. Soh JW, Weinstein IB: Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment, in Dannenberg AJ, DuBois RN (eds): COX-2: A New Target for Cancer Prevention and Treatment . New York, NY, Karger, pp 259,2003-281 · DOI
  44. 10.1172/JCI9621 · DOI
  45. 10.1074/jbc.M010787200 · DOI
  46. 10.1073/pnas.121574098 · DOI
  47. 10.1073/pnas.192323799 · DOI
  48. 10.1007/s10350-004-6418-3 · DOI
  49. 10.1093/carcin/23.9.1463 · DOI
  50. 10.1172/JCI13271 · DOI
  51. 10.1016/S0092-8674(00)81433-6 · DOI · Paper page
  52. 10.1074/jbc.272.34.21455 · DOI
  53. Roth GJ, Machuga ET, Strittmatter P: The heme-binding properties of prostaglandin synthetase from sheep vesicular gland. J Biol Chem 256:10018,1981-10022, · DOI
  54. Pagels WR, Sachs RJ, Marnett LJ, et al: Immunochemical evidence for the involvement of prostaglandin H synthase in hydroperoxide-dependent oxidations by ram seminal vesicle microsomes. J Biol Chem 258:6517,1983-6523, · DOI
  55. 10.1073/pnas.72.8.3073 · DOI
  56. Hemler M, Lands WE: Purification of the cyclooxygenase that forms prostaglandins: Demonstration of two forms of iron in the holoenzyme. J Biol Chem 251:5575,1976-5579, · DOI
  57. Merlie JP, Fagan D, Mudd J, et al: Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 263:3550,1988-3553, · DOI
  58. 10.1016/0014-5793(88)80847-0 · DOI
  59. 10.1073/pnas.85.5.1412 · DOI
  60. Fu JY, Masferrer JL, Seibert K, et al: The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265:16737,1990-16740, · DOI
  61. 10.1172/JCI114850 · DOI
  62. 10.1073/pnas.88.7.2692 · DOI
  63. Kujubu DA, Fletcher BS, Varnum BC, et al: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866,1991-12872, · DOI
  64. O'Banion MK, Sadowski HB, Winn V, et al: A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 266:23261,1991-23267, · DOI
  65. 10.1016/S1470-2045(01)00488-0 · DOI
  66. 10.1007/s004320000225 · DOI
  67. 10.1016/0092-8674(90)90186-I · DOI · Paper page
  68. 10.1074/jbc.272.1.601 · DOI
  69. 10.1053/ejso.2002.1331 · DOI
  70. 10.1038/nm993 · DOI
  71. 10.1073/pnas.93.10.4816 · DOI
  72. 10.1074/jbc.M002324200 · DOI
  73. Dixon DA: Regulation of COX-2 expression in human cancer, in Dannenberg AJ, DuBois RN (eds): COX-2: A New Target for Cancer Prevention and Treatment . New York, NY, Karger, pp 52,2003-71
  74. 10.1177/107327480200902S04 · DOI
  75. 10.1002/cncr.11387 · DOI
  76. 10.1111/j.1572-0241.2003.07328.x · DOI
  77. 10.1016/0016-5085(94)90246-1 · DOI
  78. 10.1053/gast.1996.v110.pm8613017 · DOI
  79. 10.1136/gut.38.1.79 · DOI
  80. 10.1016/S0016-5085(96)70083-5 · DOI
  81. 10.1038/sj.bjc.6600927 · DOI
  82. 10.1016/S0016-5085(00)70216-2 · DOI
  83. 10.1016/S0002-9440(10)64759-1 · DOI
  84. 10.1002/(SICI)1097-0215(19991112)83:4<470::AID-IJC6>3.0.CO;2-F · DOI
  85. 10.1038/sj.bjc.6690224 · DOI
  86. 10.1038/sj.onc.1205869 · DOI
  87. 10.1073/pnas.0435410100 · DOI
  88. 10.1007/978-1-4615-0193-0_63 · DOI
  89. Adegboyega PA, Mifflin RC, DiMari JF, et al: Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. Arch Pathol Lab Med 126:829,2002-836, · DOI
  90. 10.1172/JCI10241 · DOI
  91. 10.1056/NEJM197111182852108 · DOI · Paper page
  92. 10.1038/nm0295-149 · DOI
  93. 10.1016/S0092-8674(00)80108-7 · DOI · Paper page
  94. 10.1016/0092-8674(89)90238-9 · DOI
  95. 10.1126/science.7521539 · DOI
  96. 10.3181/00379727-172-41548 · DOI
  97. 10.1073/pnas.94.7.3336 · DOI · Paper page
  98. 10.1254/jjp.75.105 · DOI
  99. Chiarugi V, Magnelli L, Gallo O: Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review). Int J Mol Med 2:715,1998-719, · DOI
  100. 10.1038/70995 · DOI
  101. Daniel TO, Liu H, Morrow JD, et al: Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59:4574,1999-4577, · DOI
  102. 10.1038/sj.bjc.6694262 · DOI
  103. 10.1084/jem.20021408 · DOI
  104. 10.1002/path.1223 · DOI
  105. 10.1038/nm0901-1041 · DOI
  106. 10.1046/j.1365-2141.2003.04247.x · DOI
  107. Goodwin JS: Immunologic effects of nonsteroidal anti-inflammatory drugs. Am J Med 77:7,1984-15, · DOI
  108. 10.1016/S0025-7125(16)31500-0 · DOI
  109. 10.1007/BF00666103 · DOI
  110. 10.1002/1097-0142(19910915)68:6<1279::AID-CNCR2820680617>3.0.CO;2-Y · DOI
  111. 10.1002/ijc.2910470504 · DOI
  112. Brunda MJ, Herberman RB, Holden HT: Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 124:2682,1980-2687, · DOI
  113. 10.1007/BF02053754 · DOI
  114. 10.1007/BF00915791 · DOI
  115. Kambayashi T, Alexander HR, Fong M, et al: Potential involvement of IL-10 in suppressing tumor-associated macrophages: Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 154:3383,1995-3390, · DOI
  116. 10.4049/jimmunol.170.2.757 · DOI
  117. 10.1016/S0959-8049(99)00241-5 · DOI
  118. 10.1001/archotol.1992.01880050080019 · DOI
  119. 10.1096/fj.02-0417fje · DOI
  120. 10.4049/jimmunol.166.4.2674 · DOI
  121. 10.4049/jimmunol.164.1.361 · DOI
  122. 10.1093/carcin/13.6.995 · DOI
  123. 10.1002/(SICI)1096-9896(199708)182:4<392::AID-PATH874>3.0.CO;2-G · DOI
  124. 10.1007/s005950050096 · DOI
  125. 10.1016/S0016-5085(98)70305-1 · DOI
  126. 10.1016/0092-8674(95)90127-2 · DOI
  127. 10.1002/jcp.10068 · DOI
  128. 10.1038/sj.bjc.6600829 · DOI
  129. Grover JK, Yadav S, Vats V, et al: Cyclo-oxygenase 2 inhibitors: Emerging roles in the gut. Int J Colorectal Dis 18:279,2003-291, · DOI
  130. 10.1053/gast.2001.21907 · DOI
  131. Drazen JM: COX-2 inhibitors: A lesson in unexpected problems. N Engl J Med 2005 · DOI
  132. 10.1038/sj.bjc.6600867 · DOI
  133. 10.1093/carcin/bgg046 · DOI
  134. 10.1038/79534 · DOI
  135. 10.1053/gast.2001.24844 · DOI
  136. 10.1097/00000421-200110000-00005 · DOI
  137. 10.1002/ijc.11164 · DOI
  138. 10.1093/jnci/83.5.355 · DOI
  139. 10.1136/bmj.307.6899.285 · DOI
  140. 10.1093/jnci/85.15.1220 · DOI
  141. 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D · DOI
  142. 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-# · DOI
  143. 10.7326/0003-4819-121-4-199408150-00001 · DOI
  144. 10.1056/NEJM199509073331001 · DOI
  145. 10.1038/bjc.1997.444 · DOI
  146. 10.1002/(SICI)1097-0142(19980615)82:12<2326::AID-CNCR5>3.0.CO;2-Q · DOI
  147. 10.1046/j.1525-1500.1998.0OA29.x · DOI
  148. 10.1023/A:1008931708716 · DOI
  149. 10.1097/00001648-200007000-00003 · DOI
  150. 10.1159/000007745 · DOI
  151. 10.7326/0003-4819-115-12-952 · DOI
  152. 10.1016/0016-5085(91)90519-Q · DOI
  153. Tonelli F, Valanzano R: Sulindac in familial adenomatous polyposis. Lancet 342:1120,1993, · DOI
  154. 10.1056/NEJM199305063281805 · DOI
  155. 10.1002/bjs.1800801244 · DOI
  156. 10.1016/0016-5085(95)90411-5 · DOI
  157. 10.1002/(SICI)1097-0142(19961015)78:8<1660::AID-CNCR4>3.0.CO;2-I · DOI
  158. 10.1136/gut.38.4.578 · DOI
  159. 10.1007/BF02055161 · DOI

Cited by

Sorted by citations

See all 444

Metadata

Authors
Brown, J. R., & DuBois, R. N.
Affiliations
From the Vanderbilt-Ingram Cancer Center, Nashville, TN
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2005-04-20
Volume
23
Issue
12
Pages
2840-2855
ISSN
  • 0732-183X
  • 1527-7755
DOI
10.1200/jco.2005.09.051
Cited by
444
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review